Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma.

Related Articles

Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma.

Crit Rev Oncol Hematol. 2018 Jan;121:45-50

Authors: Climent MA, Muñoz-Langa J, Basterretxea-Badiola L, Santander-Lobera C

Abstract
A systematic review was conducted to identify real world studies reporting outcomes after first-line pazopanib in patients with metastatic renal cell carcinoma. Studies had to be observational and report survival data in terms of progression-free survival and overall survival in order to conduct meta-analysis techniques. These real-world data were compared to those obtained in the phase II and III randomized controlled trials of pazopanib. Real world evidence showed that the clinical and safety outcomes were consistent with those observed in the clinical trials despite the inclusion of unselected patients with a wide spectrum of prognostic features and comorbidities. Similarly to the results of the pivotal studies, good prognosis patients had the most benefit from pazopanib. Further investigation is needed to complement evidence from clinical trials, in particular focused on patient-centered outcomes.

PMID: 29279098 [PubMed - indexed for MEDLINE]

https://ift.tt/2E8A0L7